demonstrating anti-tumor activity of TL-53
◼ Results highlight specificity of TLR3-agonist TL-532, that induces lifelong anti-tumor auto-vaccination and reverses resistance to immune checkpoint inhibitors.
◼ Results to be presented at 18th Congress of Oligonucleotide Therapeutics Society (OTS) in Phoenix on October 2-5, 2022.